Plasma Neprilysin Concentrations: A New Prognostic Marker in Heart Failure?;Concentraciones plasmáticas de neprilisina: ¿un nuevo marcador pronóstico en la insuficiencia cardiaca?

Revista Espanola de Cardiologia

Volumn 68, Issue 12, 2015, Pages 1053-1055

  Richards, A Mark ^a,b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE METALLOENDOPEPTIDASE;

EDITORIAL; HEART FAILURE; PROTEIN BLOOD LEVEL; BLOOD; FEMALE; HOSPITALIZATION; HUMAN; MALE; MORTALITY;

FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; NEPRILYSIN;

EID: 85001735593     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2015.09.009     Document Type: Article

References (11)

1. Skidgel RA, Erdos EG. Angiotesnin converting enzyme (ACE) and neprilysin hydrolyse neuropeptides: A brief history, the beginning and follow-ups to early studies. Peptides. 2004;25:521-5.
2. Turner AJ, Isaac RE, Coates D. The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bio Essays. 2001;23:261-9.
3. McClean DR, Ikram H, Garlick AH, Richards AM, Nicholls MG, Crozier IG. The clinical, cardiac, renal, arterial and neurohormonal effects of Omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. J Am Coll Cardiol. 2000;36:479-86.
4. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau JL, et al; for the OVERTURE Study group. Comparison of omapatrilat and enalapril in patients with chronic heart failure. Circulation. 2002;106:920.
5. McMurray JJ, Packer M, Ashkay SD, Gong J, Lefkowitz MP, Rizkala AR, et al; for the PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993-1004.
6. Yandle TG, Richards AM, Smith MW, Charles C, Livesey JH, Espiner EA. Assay of endopeptidase-24.11 (EC3.4.24.11) activity in human plasma. Application to in vivo studies of endopeptidase inhibitors. Clin Chem. 1992;38:1785-91.
7. Bayes-Genis A, Barallat J, Galan A, de Antonio M, Domingo M, Zamora E, et al. Souble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol. 2015;65:657-65.
8. Bayes-Genis A, Barallat J, Galán A, de Antonio M, Domingo Mar, Zamora E, et al. Estrategia multimarcador para estratificar el pronóstico en insuficiencia cardiaca. Valor de los marcadores neurohumorales: neprilisina frente a NT-proBNP. Rev Esp Cardiol. 2015;68:1075-84.
9. Vodovar N, Seronde MF, Laribi S, Gayat E, Lassus J, Jnauzzi JL, et al; GREAT network. Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure. JACC Heart Fail. 2015;3:629-36.
10. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Drazner MH, et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62:147-239.
11. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Nicholls MG, Richards AM. Combined inhibition of angiotensin II and endothelin suppresses the brain natri-uretic peptide response to developing heart failure. Clin Sci. 2004;106:569-76.